Clinical Trial Update: Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, pharmacokinetics, and preliminary efficacy of intravenous OMO-103, a Myc inhibitor, in patients with metastatic pancreatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• OMO-103

Snippet

Sponsor: Peptomyc S.L. | Conditions: Metastatic Pancreatic Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING